• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Alterity Therapeutics Limited

    5/12/25 8:01:17 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATHE alert in real time by email
    6-K 1 ea0241694-6k_alterity.htm REPORT OF FOREIGN PRIVATE ISSUER
     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-163

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of May 2025

     

    Alterity Therapeutics Limited

    (Name of Registrant)

     

    Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia

    (Address of Principal Executive Office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒       Form 40-F ☐

     

    This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

     

     

     

     

     

     

    ALTERITY THERAPEUTICS LIMITED

    (a development stage enterprise)

     

    The following exhibits are submitted:

     

    99.1   Alterity Prominently Featured at International MSA Congress

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Alterity Therapeutics Limited
         
      By: /s/ Geoffrey P. Kempler
        Geoffrey P. Kempler
        Chairman

     

    Date: May 12, 2025

     

     

    2

    Get the next $ATHE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATHE

    DatePrice TargetRatingAnalyst
    2/3/2025Speculative Buy → Hold
    The Benchmark Company
    12/12/2024$8.00Buy
    Maxim Group
    8/20/2021$4.00Speculative Buy
    Benchmark
    More analyst ratings

    $ATHE
    SEC Filings

    See more
    • SEC Form 6-K filed by Alterity Therapeutics Limited

      6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)

      5/12/25 8:01:17 AM ET
      $ATHE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Alterity Therapeutics Limited

      6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)

      5/12/25 8:00:14 AM ET
      $ATHE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Alterity Therapeutics Limited

      6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)

      5/7/25 8:00:18 AM ET
      $ATHE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATHE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alterity Therapeutics Prominently Featured at the International MSA Congress

      – ATH434 Phase 2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints – – MSA Atrophy Index (MSAai) enhances MSA diagnosis and monitoring – – bioMUSE Study shows higher α- synuclein concentration is associated with greater burden of orthostatic symptoms – MELBOURNE, Australia and SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that several oral and poster presentations related to Alterity's clinical programs in Multiple System Atrophy (MSA) were featured at the

      5/12/25 7:35:00 AM ET
      $ATHE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

      MELBOURNE, Australia and SAN FRANCISCO, May 07, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that multiple oral and poster presentations related to Alterity's clinical programs in Multiple System Atrophy (MSA) will be featured at the 2025 International MSA Congress taking place May 9 - 11, 2025 in Boston, MA, USA. The Congress is presented by Mission MSA, a non-profit organization dedicated to improving the quality of life and building hope for people affected by MSA through support services, educational resou

      5/7/25 8:16:45 AM ET
      $ATHE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

      – Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA – MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ATH434 for the treatment of Multiple System Atrophy (MSA). This designation is intended to accelerate the development and review of novel investigational products such as ATH434 and recognizes its potential as an innovative

      5/5/25 7:35:00 AM ET
      $ATHE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATHE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alterity Therapeutics downgraded by The Benchmark Company

      The Benchmark Company downgraded Alterity Therapeutics from Speculative Buy to Hold

      2/3/25 7:02:17 AM ET
      $ATHE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on Alterity Therapeutics with a new price target

      Maxim Group initiated coverage of Alterity Therapeutics with a rating of Buy and set a new price target of $8.00

      12/12/24 8:39:51 AM ET
      $ATHE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benchmark initiated coverage on Alterity Therapeutics with a new price target

      Benchmark initiated coverage of Alterity Therapeutics with a rating of Speculative Buy and set a new price target of $4.00

      8/20/21 7:25:55 AM ET
      $ATHE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATHE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Alterity Therapeutics Limited (Amendment)

      SC 13D/A - ALTERITY THERAPEUTICS LTD (0001131343) (Subject)

      10/31/22 5:29:16 PM ET
      $ATHE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Alterity Therapeutics Limited (Amendment)

      SC 13D/A - ALTERITY THERAPEUTICS LTD (0001131343) (Subject)

      8/26/22 5:16:24 PM ET
      $ATHE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Alterity Therapeutics Limited (Amendment)

      SC 13D/A - ALTERITY THERAPEUTICS LTD (0001131343) (Subject)

      8/1/22 5:21:53 PM ET
      $ATHE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATHE
    Leadership Updates

    Live Leadership Updates

    See more
    • Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

      MELBOURNE, Australia and SAN FRANCISCO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), has announced the appointment of Abby Macnish Niven as Alterity's Company Secretary following her appointment as Chief Financial Officer of Alterity. Ms Macnish Niven assumes the role of Company Secretary from Mr Phillip Hains effective on 18 November 2024. The Board and Management of Alterity thank Phillip for his valuable contributions over the past several years and appreciate the foundation he helped establish. Ms Macnish Niven was appointed as CFO on 30 September 2024 and has extensive experience in private wealth man

      11/19/24 7:25:00 AM ET
      $ATHE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

      MELBOURNE, Australia and SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, announced the appointment of Abby Macnish Niven as the Company's Chief Financial Officer (CFO), effective today. "We look forward to Abby's contributions whose broad experience and financial background will help us advance our programs. I would also like to express my gratitude to Phillip and his team who supported us during a transition period," said David Stamler, M.D., Chief Executive Officer of Alterity. Ms Macnish Niven h

      9/30/24 7:35:00 AM ET
      $ATHE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer

      MELBOURNE, Australia and SAN FRANCISCO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the appointment of Phillip Hains as the Company's new Chief Financial Officer (CFO), effective 31 January 2024. Mr. Hains has served as the Company Secretary of Alterity since 2014, and his experience includes almost 30 years in corporate secretarial, accounting and general management through professional services firm Acclime and predecessor firm The CFO Solution. The appointment of Mr. Hains follows the resignatio

      12/21/23 12:30:00 AM ET
      $ATHE
      Biotechnology: Pharmaceutical Preparations
      Health Care